TS
BBIO icon

Thomas Steyer’s BridgeBio Pharma BBIO Stock Holding History

Thomas Steyer’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$800M Buy
10,743,063
+1,377,600
+15% +$96.5M 3.69% 4
2026
Q1 		$695M Buy
9,365,463
+367,000
+4% +$26.6M 3.65% 7
2025
Q4 		$688M Buy
8,998,463
+806,463
+10% +$52.9M 2.98% 11
2025
Q3 		$425M Buy
8,192,000
+292,000
+4% +$14.2M 1.74% 19
2025
Q2 		$341M Buy
7,900,000
+2,169,000
+38% +$78.9M 1.43% 29
2025
Q1 		$198M Buy
5,731,000
+1,536,000
+37% +$51.8M 0.95% 37
2024
Q4 		$115M Buy
4,195,000
+2,448,000
+140% +$63.3M 0.51% 50
2024
Q3 		$44.5M Buy
+1,747,000
New +$45.9M 0.2% 69
2024
Q1 		– Sell
-6,000
Closed -$242K – 176
2023
Q4 		$242K Buy
+6,000
New +$180K ﹤0.01% 120

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's BBIO Position: Q2 2026 in Review

Thomas Steyer increased its BridgeBio Pharma (BBIO) stake by 15% in Q2 2026, buying an estimated $96.5M and bringing the position to 10,743,063 shares worth $800M. The position accounts for 3.69% of the portfolio, ranked #4.

Thomas Steyer first reported a position in BBIO in Q4 2023 and has held it in 9 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Thomas Steyer held 10,743,063 shares of BridgeBio Pharma worth $800M as of Q2 2026.
  • Thomas Steyer bought 1,377,600 BridgeBio Pharma shares in Q2 2026, an estimated $96.5M.
  • BridgeBio Pharma made up 3.69% of Thomas Steyer's portfolio in Q2 2026, its #4 holding.
  • Thomas Steyer first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 9 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.